Invitae Management

Management criteria checks 1/4

Invitae's CEO is Ken Knight, appointed in Jul 2022, has a tenure of 2.08 years. directly owns 0.11% of the company’s shares, worth $122.69. The average tenure of the management team and the board of directors is 1.4 years and 3.9 years respectively.

Key information

Ken Knight

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	2.1yrs
CEO ownership	0.1%
Management average tenure	1.4yrs
Board average tenure	3.9yrs

Recent management updates

Recent updates

Cautious Investors Not Rewarding Invitae Corporation's (NYSE:NVTA) Performance Completely

Dec 20

Invitae maintains 2022 financial guidance as Q2 results beat on top and bottom lines

Aug 09

CEO Compensation Analysis

How has Ken Knight's remuneration changed compared to Invitae's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2023	n/a	n/a	-US$1b
Jun 30 2023	n/a	n/a	-US$800m
Mar 31 2023	n/a	n/a	-US$3b
Dec 31 2022	US$5m	US$611k	-US$3b
Sep 30 2022	n/a	n/a	-US$3b
Jun 30 2022	n/a	n/a	-US$3b
Mar 31 2022	n/a	n/a	-US$451m
Dec 31 2021	US$4m	US$500k	-US$379m
Sep 30 2021	n/a	n/a	-US$408m
Jun 30 2021	n/a	n/a	-US$313m
Mar 31 2021	n/a	n/a	-US$613m
Dec 31 2020	US$11m	US$250k	-US$602m

Compensation vs Market: Insufficient data to establish whether Ken's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Ken's compensation has increased whilst the company is unprofitable.

CEO

Ken Knight (63 yo)

2.1yrs

Tenure

US$4,950,752

Compensation

Mr. Kenneth D. Knight, also known as Ken, serves as Independent Director at Simpson Manufacturing Co., Inc. since June 21, 2021. He was the Chief Operating Officer at Invitae Corporation since June 29, 202...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Randal Scott	Co-Founder & Chairman of the Board	2.1yrs	US$256.34k	0.034% $ 38.8
Kenneth Knight	President	2.1yrs	US$4.95m	0.11% $ 122.7
Thomas Brida	General Counsel	7.6yrs	US$2.15m	0.091% $ 103.8
Ana Schrank	Chief Accounting Officer & CFO	less than a year	no data	no data
David Sholehvar	Chief Operating Officer	less than a year	no data	no data
Hoki Luk	Head of Investor Relations and Capital Markets & Corporate Development	no data	no data	no data
Shelly Guyer	Chief Sustainability Officer	3.2yrs	US$2.25m	no data
Desarie French	Chief Talent Officer	no data	no data	no data
W. Korn	Chief Medical Officer	1.4yrs	no data	no data
Robert Guigley	Chief Commercial Officer	less than a year	no data	no data
Jackson Finks	Director of Investor Relations & Strategic Finance	no data	no data	no data

1.4yrs

Average Tenure

58yo

Average Age

Experienced Management: NVTA.Q's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Randal Scott	Co-Founder & Chairman of the Board	2.1yrs	US$256.34k	0.034% $ 38.8
Kenneth Knight	President	2.1yrs	US$4.95m	0.11% $ 122.7
Eric Aguiar	Lead Independent Director	13.9yrs	US$408.60k	0.0040% $ 4.6
Christine Gorjanc	Independent Director	8.8yrs	US$301.21k	0.0030% $ 3.4
William Osborne	Independent Director	1.6yrs	no data	no data
Geoffrey Crouse	Independent Director	12.4yrs	US$298.71k	0.0097% $ 11.1
Chitra Nayak	Independent Director	5.9yrs	US$278.71k	0.0030% $ 3.4
Kimber Lockhart	Independent Director	3.9yrs	US$288.71k	0.0030% $ 3.4
Jill Frizzley	Director	less than a year	no data	no data

3.9yrs

Average Tenure

62yo

Average Age

Experienced Board: NVTA.Q's board of directors are considered experienced (3.9 years average tenure).

Invitae Management

Management criteria checks 1/4

Key information

Recent management updates

Invitae Corporation Announces Board Changes

Invitae Corporation Announces the Retirement of Robert L. Nussbaum as Chief Medical Officer, Effective December 29, 2023

Invitae Corporation Appoints Ana J. Schrank as Chief Accounting Officer

Invitae Corporation Appoints David Sholehvar as Chief Operating Officer, Effective November 13, 2023

Invitae Corporation Announces Change of Chief Financial Officer, Effective October 2, 2023

Invitae Corporation Announces Executive Changes

Recent updates

Invitae Launches Unlock Behind the Seizure Program for Pediatric Epilepsy Patients

First Amended Disclosure Statement Approved for Invitae Corporation

Laboratory Corporation of America Holdings (NYSE:LH) agreed to acquire Substantially all Assets of Invitae Corporation for approximately $240 million.

Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance

Invitae Launches Update to Invitae Generation: Clinical Variant Modeling Improves Variant Classification

Invitae Corporation Provides Unaudited Earnings Guidance for the Fourth Quarter and Full Year of 2023

Motion for Asset Sale Filed by Invitae Corporation

Invitae Corporation Filed for Bankruptcy

Invitae Corporation(OTCPK:NVTA) dropped from S&P TMI Index

The New York Stock Exchange to Commence Delisting Proceedings against Invitae

Invitae Corporation May File for Bankruptcy

New minor risk - Market cap size

Cautious Investors Not Rewarding Invitae Corporation's (NYSE:NVTA) Performance Completely

Invitae Corporation Announces Board Changes

Invitae Corporation Announces the Retirement of Robert L. Nussbaum as Chief Medical Officer, Effective December 29, 2023

Price target decreased by 11% to US$1.31

Invitae Corporation Appoints Ana J. Schrank as Chief Accounting Officer

Consensus EPS estimates fall by 119%

New major risk - Financial position

Invitae Corporation Reaffirms Earnings Guidance for the Full Year 2023

Price target increased by 30% to US$1.92

Third quarter 2023 earnings: EPS misses analyst expectations

Invitae Corporation to Report Q3, 2023 Results on Nov 08, 2023

Invitae Corporation Announces Findings from the Study to Date on Uncertain Results from Hereditary Disease Genetic Testing

Invitae Corporation Appoints David Sholehvar as Chief Operating Officer, Effective November 13, 2023

Price target decreased by 14% to US$1.58

Invitae Announces Results of Its Collaborative Study on Universal Hereditary Cancer Genetic Testing in All Patients with Breast Cancer in A Rural Population in the Annals of Surgical Oncology

Invitae Corporation Announces Change of Chief Financial Officer, Effective October 2, 2023

Invitae Receives Notice of Non-Compliance with NYSE Minimum Share Price Continued Listing Standard

Invitae Receives Notice of Non-Compliance with NYSE Minimum Share Price Continued Listing Standard

New major risk - Financial position

Invitae Corporation Announces Clinical Trial Results Support Genetic Testing of All Patients with Prostate Cancer

Price target decreased by 13% to US$1.70

Consensus EPS estimates fall by 34%

Invitae Corporation Provides Revenue Guidance for the Year 2023

Invitae Corporation Provides Revenue Guidance for the Year 2023

Price target decreased by 8.2% to US$1.87

Second quarter 2023 earnings: EPS misses analyst expectations

Invitae: Revenue Troubles Build

Invitae Corporation to Report Q2, 2023 Results on Aug 08, 2023

Invitae Is Treading In Competitive Waters

Invitae Corporation Announces Executive Changes

Invitae Corporation's (NYSE:NVTA) Prospects Need A Boost To Lift Shares

Invitae Corporation Announces Nine Studies to Be Presented At the 2023 American Society of Clinical Oncology Annual Meeting Reinforce the Critical Role of Germline Genetic Testing in Oncology

Invitae Announces CFO Changes

President recently sold US$54k worth of stock

Invitae Corporation Announces It Intends to Appeal the Verdict Delivered by A Jury At the United States District Court

Consensus EPS estimates fall by 19%

First quarter 2023 earnings: EPS misses analyst expectations

Price target decreased by 10.0% to US$2.26

Full year 2022 earnings: EPS misses analyst expectations

Invitae Corporation to Report Q4, 2022 Results on Feb 28, 2023

Price target decreased by 7.4% to US$2.51

Invitae Corporation Appoints William H. Osborne to its Board of Directors

Invitae: What Happened At The JP Morgan Health Conference

Invitae guides Q4 revenue above estimates

Director recently sold US$115k worth of stock

Invitae Likely Hasn't Reached The Bottom Yet

Invitae Releases Data Use Transparency Report, Demonstrating the Impact of Patient Data on Genetic Research

Invitae Launches Rare Patient Network for Pediatric Patients with Rare Neurodevelopmental Diseases

Consensus forecasts updated

Invitae: This Turnaround Could Be Painful

Invitae Corporation Reiterates Earnings Guidance for the Year 2022

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Invitae Corporation Reports Asset Impairments for the Third Quarter Ended September 30, 2022

Invitae GAAP EPS of -$1.27 misses by $0.43, revenue of $133.54M beats by $2.16M

Invitae Corporation Study Shows Therapy Informed by Genetic Testing Reduces Seizures in Some Patients with Epilepsy

Invitae Corporation to Report Q3, 2022 Results on Nov 08, 2022

Price target decreased to US$2.71